Radu Pompilia, Ebadi Maryam, Montano-Loza Aldo J, Dufour Jean Francois
Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, 3008 Bern, Switzerland.
Division of Gastroenterology & Liver Unit, University of Alberta, Edmonton, AB T6G 2X8, Canada.
Cancers (Basel). 2022 Oct 27;14(21):5290. doi: 10.3390/cancers14215290.
In the last decade, body composition (BC) assessment has emerged as an innovative tool that can offer valuable data concerning nutritional status in addition to the information provided by the classical parameters (i.e., body mass index, albumin). Furthermore, published data have revealed that different types of body composition are associated with different outcomes. For example, abnormalities of skeletal muscle, a common finding in cirrhotic and oncologic patients, are associated with poor outcome (i.e., high morbidity and high mortality). The disposition (visceral/subcutaneous adipose tissue) and radiodensity of adipose tissue proved to also be determinant factors for HCC outcome. Despite all the advantages, BC assessment is not part of the standard pre-therapeutic workup. The main reasons are the high heterogeneity of data, the paucity of prospective studies, the lack of a standard assessment method, and the interpopulation variation of BC. This paper aims to review the available evidence regarding the role of BC as a prognostic tool in the HCC population undergoing various therapies.
在过去十年中，身体成分（BC）评估已成为一种创新工具，除了经典参数（即体重指数、白蛋白）提供的信息外，它还能提供有关营养状况的有价值数据。此外，已发表的数据表明，不同类型的身体成分与不同的结果相关。例如，骨骼肌异常在肝硬化和肿瘤患者中很常见，与不良预后（即高发病率和高死亡率）相关。脂肪组织的分布（内脏/皮下脂肪组织）和放射密度也被证明是肝癌预后的决定性因素。尽管有所有这些优点，但BC评估并非标准治疗前检查的一部分。主要原因是数据高度异质性、前瞻性研究匮乏、缺乏标准评估方法以及BC的人群间差异。本文旨在综述关于BC作为接受各种治疗的肝癌人群预后工具作用的现有证据。
